Financials
Financial year 2025
Worth noting
- A loss two years in a row.
Gross margin
€ -196,240
▲ 90% vs 2024
Profit
Caution€ -607,875
▲ 77% vs 2024
Debts
Low€ 12,356
▼ 96% vs 2024
NeGIO Therapeutics from Ottignies-Louvain-la-Neuve, company number BE0799822012, closed financial year 2025 with a result of € -607,875 after tax. For that financial year NeGIO Therapeutics recorded a gross margin of € -196,240 and equity of € 4.8 million. Compared with financial year 2024, the result moved from € -2.7 million to € -607,875. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on May 26, 2026.
What happened at NeGIO Therapeutics?
What happened at NeGIO Therapeutics in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- AdBio Partners SAS stepped down as director. NBB
- Jan Van den Bossche stepped down as director. NBB
- Vives Partners SRL stepped down as director. NBB
- Thierry Hercend stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 607,875. Source: NBB ↗
- AdBio Partners SAS became a director. NBB
- Vives Partners SRL became a director. NBB
- New establishment in Sint-Lambrechts-Woluwe. KBO
In short
From € 2.1 million loss in 2023 to € 607,875 loss in 2025.
Paid € 912 in corporate taxes since 2023.
A new publication or filing at NeGIO Therapeutics? We notify you, reason included.
Follow NeGIO TherapeuticsNeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
Directors
According to the 2025 annual accounts
Director · represented by Alain Huriez
since 2025 · until 2029
Jan Van den Bossche
Director
since 2023 · until 2029
Director · represented by Philippe Durieux
Also active at: NOVADIP BIOSCIENCES, TESSARES, AXINESIS +9 more
since 2024 · until 2029
Thierry Hercend
Director
since 2023 · until 2029
Establishments
Establishment units
Physical locations of this company
Chemin du Cyclotron 6
1348 Ottignies-Louvain-la-Neuve
Hippokrateslaan 75
1200 Sint-Lambrechts-Woluwe
Active since 3 July 2023
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 88 companies are registered at this address.
RECHERCHES ET APLLICATIONS MARKETING
GOLDEM
€ 61,314 gross margin · 2024
ArteCom
€ -10,166 gross margin · 2025
ARCADIA
€ 690 gross margin · 2025
ARTEMIS MEDICAL
€ 59,361 gross margin · 2025
+83 more
Details
- Company number
- 0799.822.012
- VAT number
- BE 0799.822.012
- Registered office
- Chemin du Cyclotron 6, 1348 Ottignies-Louvain-la-Neuve
- Names & denominations
- NeGIO Therapeutics · NeGIO
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 22 March 2023
- Peppol
- Active · Active since 31 Dec 2025
- Activities · NACE
Vervaardiging van farmaceutische grondstoffen